Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a business update and outlook for the development of its lead product ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it will present additional data highlighting the use of the ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and ...
The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment ...
Mendus AB Annual stock financials by MarketWatch. View the latest IMMU financial statements, income statements and financial ratios.
Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine. Mendus, a biopharmaceutical company focused on immunotherapies ...
ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, following positive initial FDA ...
Preparations for pivotal-stage readiness of vididencel in AML on track The hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results